MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice
暂无分享,去创建一个
M. Essig | À. Rovira | M. Weller | A. Dörfler | S. Combs | M. Law | Seung-Koo Lee | N. Anzalone | M. Weller | P. Picozzi | S. Lee | S. Combs | S. Combs
[1] Rohit Bakshi,et al. Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis , 2011, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[2] T. Mikkelsen,et al. In Vivo Correlation of Tumor Blood Volume and Permeability with Histologic and Molecular Angiogenic Markers in Gliomas , 2011, American Journal of Neuroradiology.
[3] Bram Stieltjes,et al. Biopsy Targeting Gliomas: Do Functional Imaging Techniques Identify Similar Target Areas? , 2010, Investigative radiology.
[4] E. Shaw,et al. Radiation oncology in brain tumors: current approaches and clinical trials in progress. , 2010, Neuroimaging clinics of North America.
[5] N. Anzalone. Comparative Studies of Different Gadolinium Agents in Brain Tumors: Differences between Gadolinium Chelates and Their Possible Influence on Imaging Features , 2010, American Journal of Neuroradiology.
[6] M. Forsting,et al. Prevalence of acute adverse reactions to gadobutrol--a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. , 2010, European journal of radiology.
[7] S. Lee,et al. Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine , 2010, American Journal of Neuroradiology.
[8] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] V. Runge,et al. Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: Comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T , 2010, Journal of magnetic resonance imaging : JMRI.
[10] T. Struffert,et al. Dynamic contrast enhancement of experimental glioma an intra-individual comparative study to assess the optimal time delay. , 2010, Academic radiology.
[11] S. Cha,et al. Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient Is Predictive of Clinical Outcome in Primary Central Nervous System Lymphoma , 2010, American Journal of Neuroradiology.
[12] G. Reifenberger,et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Law,et al. Magnetic resonance perfusion and permeability imaging in brain tumors. , 2009, Neuroimaging clinics of North America.
[14] M. Law. Neurological complications. , 2009, Cancer imaging : the official publication of the International Cancer Imaging Society.
[15] R. Scotti,et al. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine , 2009, Acta radiologica.
[16] J. Polimeni,et al. 96‐Channel receive‐only head coil for 3 Tesla: Design optimization and evaluation , 2009, Magnetic resonance in medicine.
[17] Soonmee Cha,et al. Neuroimaging in neuro-oncology , 2009, Neurotherapeutics.
[18] Patrick Y Wen,et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Kauczor,et al. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 tesla , 2009, Acta radiologica.
[20] Toshinori Hirai,et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. , 2009, Radiology.
[21] S. Schoenberg,et al. Comparative Evaluation of Lesion Enhancement Using 1 M Gadobutrol vs. 2 Conventional Gadolinium Chelates, All at a Dose of 0.1 mmol/kg, in a Rat Brain Tumor Model at 3 T , 2009, Investigative radiology.
[22] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[23] Susan Chang,et al. Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.
[24] J. Maldjian,et al. Multicenter, double‐blind, randomized, intra‐individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla , 2009, Journal of magnetic resonance imaging : JMRI.
[25] À. Rovira,et al. Proton MR Spectroscopy Improves Discrimination between Tumor and Pseudotumoral Lesion in Solid Brain Masses , 2009, American Journal of Neuroradiology.
[26] T. Frenzel,et al. Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents in Human Serum at 37°C , 2008, Investigative radiology.
[27] E. Kanal,et al. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23,553 administrations of gadobenate dimeglumine. , 2008, AJR. American journal of roentgenology.
[28] J. Maldjian,et al. Contrast-Enhanced MR Imaging of Brain Lesions: A Large-Scale Intraindividual Crossover Comparison of Gadobenate Dimeglumine versus Gadodiamide , 2008, American Journal of Neuroradiology.
[29] Holly Ning,et al. Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas , 2008, Radiation oncology.
[30] Lawrence L. Wald,et al. Event-related single-shot volumetric functional magnetic resonance inverse imaging of visual processing , 2008, NeuroImage.
[31] T. Frenzel,et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.
[32] A. Brandes,et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.
[33] M. Bellin,et al. Extracellular gadolinium-based contrast media: differences in diagnostic efficacy. , 2008, European journal of radiology.
[34] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[35] Dieta Brandsma,et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.
[36] A. Doerfler,et al. High-molar contrast agents for CNS application , 2008 .
[37] S. Stuckey,et al. Hyperintensity in the subarachnoid space on FLAIR MRI. , 2007, AJR. American journal of roentgenology.
[38] M. Knopp,et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. , 2007, Journal of neurosurgery.
[39] Wei Chen. Clinical Applications of PET in Brain Tumors* , 2007, Journal of Nuclear Medicine.
[40] R. Quencer,et al. Metabolite Findings in Tumefactive Demyelinating Lesions Utilizing Short Echo Time Proton Magnetic Resonance Spectroscopy , 2007, American Journal of Neuroradiology.
[41] S. Schoenberg,et al. Brain Tumor Enhancement in MR Imaging at 3 Tesla: Comparison of SNR and CNR Gain Using TSE and GRE Techniques , 2007, Investigative radiology.
[42] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[43] Sukru Mehmet Erturk,et al. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions. , 2007, AJR. American journal of roentgenology.
[44] Gerhard Adam,et al. Clinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA) , 2007, Investigative radiology.
[45] M. Knopp,et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. , 2006, Radiology.
[46] L. Wald,et al. 32‐channel 3 Tesla receive‐only phased‐array head coil with soccer‐ball element geometry , 2006, Magnetic resonance in medicine.
[47] F. Zanella,et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.
[48] Mike P. Wattjes,et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T , 2006, European Radiology.
[49] W. Yuh,et al. Contrast-Enhanced Magnetic Resonance Imaging of Central Nervous System Tumors: Agents, Mechanisms, and Applications , 2006, Topics in magnetic resonance imaging : TMRI.
[50] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[51] S. Cha,et al. Update on brain tumor imaging: from anatomy to physiology. , 2006, AJNR. American journal of neuroradiology.
[52] M. Essig,et al. Intraindividual Comparison of Gadobenate Dimeglumine and Gadobutrol for Cerebral Magnetic Resonance Perfusion Imaging at 1.5 T , 2006, Investigative radiology.
[53] G Johnson,et al. Comparison of microvascular permeability measurements, K(trans), determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. , 2006, AJNR. American journal of neuroradiology.
[54] Val M Runge,et al. Brain Tumor Enhancement in Magnetic Resonance Imaging: Comparison of Signal-to-Noise Ratio (SNR) and Contrast-to-Noise Ratio (CNR) at 1.5 Versus 3 Tesla , 2005, Investigative radiology.
[55] Wen Qin,et al. Diffusion tensor tractography in patients with cerebral tumors: a helpful technique for neurosurgical planning and postoperative assessment. , 2005, European journal of radiology.
[56] J. Mintorovitch,et al. Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.
[57] M. Port,et al. How to Compare the Efficiency of Albumin-Bound and Nonalbumin-Bound Contrast Agents In Vivo: The Concept of Dynamic Relaxivity , 2005, Investigative radiology.
[58] Andrew L Alexander,et al. Diffusion Tensor Imaging in Cerebral Tumor Diagnosis and Therapy , 2004, Topics in magnetic resonance imaging : TMRI.
[59] Khader M Hasan,et al. Diffusion tensor eigenvector directional color imaging patterns in the evaluation of cerebral white matter tracts altered by tumor , 2004, Journal of magnetic resonance imaging : JMRI.
[60] E. Shaw,et al. Current controversies in the radiotherapeutic management of adult low-grade glioma. , 2004, Seminars in oncology.
[61] J. Le Bas,et al. In Vivo Measurement of Gadolinium Concentration in a Rat Glioma Model by Monochromatic Quantitative Computed Tomography: Comparison Between Gadopentetate Dimeglumine and Gadobutrol , 2004, Investigative radiology.
[62] R. Pickering,et al. The effectiveness of implementing a care pathway for femoral neck fracture in older people: a prospective controlled before and after study. , 2004, Age and ageing.
[63] Glyn Johnson,et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.
[64] D. Birchall,et al. Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis. , 2003, The British journal of radiology.
[65] Soonmee Cha,et al. Perfusion MR imaging: basic principles and clinical applications. , 2003, Magnetic resonance imaging clinics of North America.
[66] Mauricio Castillo,et al. MR spectroscopy of brain tumors. , 2003, Magnetic resonance imaging clinics of North America.
[67] E. Shaw,et al. Prospective clinical trials of intracranial low-grade glioma in adults and children. , 2003, Neuro-oncology.
[68] Siegfried Trattnig,et al. Effect of Contrast Dose and Field Strength in the Magnetic Resonance Detection of Brain Metastases , 2003, Investigative radiology.
[69] S. Nelson. Multivoxel magnetic resonance spectroscopy of brain tumors. , 2003, Molecular cancer therapeutics.
[70] A. Sorensen,et al. Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. , 2003, Radiology.
[71] A. Jackson,et al. Reproducibility of quantitative dynamic contrast-enhanced MRI in newly presenting glioma. , 2003, The British journal of radiology.
[72] Soonmee Cha,et al. Imaging Glioblastoma Multiforme , 2003, Cancer journal.
[73] S. Cha,et al. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion , 2002, Neuroradiology.
[74] Meng Law,et al. Proton MR spectroscopy of tumefactive demyelinating lesions. , 2002, AJNR. American journal of neuroradiology.
[75] Glyn Johnson,et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. , 2002, Radiology.
[76] C. Colosimo,et al. Gadobenate dimeglumine‐enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation , 2001, Journal of magnetic resonance imaging : JMRI.
[77] V. Runge,et al. Central Nervous System: Review of Clinical Use of Contrast Media , 2001, Topics in magnetic resonance imaging : TMRI.
[78] S. Nelson. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors , 2001, Magnetic resonance in medicine.
[79] M P Carol,et al. MR-spectroscopy guided target delineation for high-grade gliomas. , 2001, International journal of radiation oncology, biology, physics.
[80] M. McNamara,et al. Phase Iii, Randomized, Double-Blind, Cross-Over Comparison of Gadoteridol and Gadopentetate Dimeglumine in Magnetic Resonance Imaging of Patients with Intracranial Lesions , 2001, Australasian radiology.
[81] G. Johnson,et al. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. , 2001, AJNR. American journal of neuroradiology.
[82] R. Gonzalez,et al. Diffusion-weighted MR imaging of the brain. , 2000, Radiology.
[83] M. Filippi,et al. Vanishing Balò-like lesions in multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.
[84] T. Benner,et al. Cerebral MR perfusion imaging: First clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double‐blinded randomized dose‐finding study , 2000, Journal of magnetic resonance imaging : JMRI.
[85] A. Jackson,et al. Improved 3D quantitative mapping of blood volume and endothelial permeability in brain tumors , 2000, Journal of magnetic resonance imaging : JMRI.
[86] G. R. Stevens,et al. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). , 2000, Investigative radiology.
[87] J. Petrella,et al. MR perfusion imaging of the brain: techniques and applications. , 2000, AJR. American journal of roentgenology.
[88] W P Dillon,et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. , 2000, AJNR. American journal of neuroradiology.
[89] W. Shabana,et al. Use of diffusion-weighted MR imaging in differential diagnosis between intracerebral necrotic tumors and cerebral abscesses. , 1999, AJNR. American journal of neuroradiology.
[90] M. Horsfield,et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. , 1998, Brain : a journal of neurology.
[91] D. Arnold,et al. In vivo differentiation of astrocytic brain tumors and isolated demyelinating lesions of the type seen in multiple sclerosis using 1H magnetic resonance spectroscopic imaging , 1998, Annals of neurology.
[92] G. Sze,et al. Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. , 1998, AJNR. American journal of neuroradiology.
[93] N. Lundbom,et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. , 1997, Journal of Neurosurgery.
[94] W. Pegios,et al. [Diagnosis of cerebral metastasis with standard dose gadobutrol vs. a high dose protocol. Intraindividual evaluation of a phase II high dose study]. , 1995, Der Radiologe.
[95] K. L. Nelson,et al. Clinical safety of gadopentetate dimeglumine. , 1995, Radiology.
[96] E. Larsson,et al. Brain Metastases — Comparison of Gadodiamide Injection-Enhanced MR Imaging at Standard and High Dose, Contrast-Enhanced CT and Non-Contrast-Enhanced MR Imaging , 1995, Acta radiologica.
[97] S. Holtås,et al. Contrast-enhanced MRI of the central nervous system: Comparison between gadodiamide injection and gadolinium-DTPA , 1995, Neuroradiology.
[98] W. Yuh,et al. The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. , 1995, AJNR. American journal of neuroradiology.
[99] M Oudkerk,et al. Safety and Efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in Magnetic Resonance Imaging of the Central Nervous System , 1995, Investigative radiology.
[100] S. Cook,et al. Triple‐Dose Versus Single‐Dose Gadoteridol in Multiple Sclerosis Patients , 1994, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[101] W. Yuh,et al. Dose of contrast material in the MR imaging evaluation of central nervous system tumors , 1994, Journal of magnetic resonance imaging : JMRI.
[102] P. Kelly,et al. Computed tomography and histologic limits in glial neoplasms: tumor types and selection for volumetric resection. , 1993, Surgical neurology.
[103] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] C R Bird,et al. Gliomas: classification with MR imaging. , 1990, Radiology.
[105] P. Kelly,et al. Volumetric stereotactic surgical resection of intra-axial brain mass lesions. , 1988, Mayo Clinic proceedings.
[106] R. Floris,et al. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. , 2013, European journal of radiology.
[107] Armin Thron,et al. Diagnostic Accuracy of MRI Compared to CCT in Patients with Brain Metastases , 2004, Journal of Neuro-Oncology.
[108] J. Valk,et al. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system , 2004, Neuroradiology.
[109] S. Nelson. Multivoxel magnetic resonance spectroscopy of brain tumors. , 2003, Molecular cancer therapeutics.
[110] A. Jackson,et al. Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data. , 2003, The British journal of radiology.
[111] W. Dillon,et al. Quantitative estimation of microvascular permeability in human brain tumors: correlation of dynamic Gd-DTPA-enhanced MR imaging with histopathologic grading. , 2002, Academic radiology.
[112] V. Runge,et al. Principles of contrast enhancement in the evaluation of brain diseases: An overview , 1997, Journal of magnetic resonance imaging : JMRI.
[113] M. Oudkerk,et al. Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. , 1997, Magnetic resonance imaging.
[114] V. Runge,et al. High‐dose gadoteridol in MR imaging of intracranial neoplasms , 1992, Journal of magnetic resonance imaging : JMRI.
[115] P. Kelly. Stereotactic imaging, surgical planning and computer-assisted resection of intracranial lesions: methods and results. , 1990, Advances and technical standards in neurosurgery.
[116] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.
[117] I. Kaplan,et al. Radiation Therapy , 2006 .